Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

Table 2 **Adjusted mean change* from baseline to last value on treatment in total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides**

		Linagliptin 5 mg (n = 366^†)	Placebo (n = 146^†)
		Mean (SE)	Mean (SE)
Total cholesterol, mg/dl	Baseline	180.4 (1.1)	177.2 (1.6)
	Change from baseline	-0.4 (1.0)	2.1 (1.3)
	Placebo-corrected difference	-1.8 (1.4)	—
	95% CI	-4.4, 0.9	—
	P value	0.195	—
LDL, mg/dl	Baseline	144.5 (1.9)	142.3 (2.9)
	Change from baseline	2.2 (1.8)	4.1 (2.3)
	Placebo-corrected difference	-1.8 (2.4)	—
	95% CI	-6.6, 3.0	—
	P value	0.452	—
HDL, mg/dl	Baseline	40.2 (1.1)	40.0 (1.9)
	Change from baseline	1.5 (0.6)	2.6 (0.8)
	Placebo-corrected difference	-1.2 (0.8)	—
	95% CI	-2.8, 0.5	—
	P value	0.172	—
Triglycerides, mg/dl	Baseline	272.6 (12.5)	241.0 (10.1)
	Change from baseline	-18.5 (7.7)	-13.5 (9.9)
	Placebo-corrected difference	-5.0 (10.6)	—
	95% CI	-25.9, 15.9	—
	P value	0.6360	—
SBP, mm Hg	Baseline	137.8 (0.8)	134.8 (1.3)
	Change from baseline	-2.9 (0.9)	-2.4 (1.2)
	Placebo-corrected difference	-0.6 (1.3)	—
	95% CI	-3.1, 2.0	—
	P value	0.664	—
DBP, mm Hg	Baseline	80.5 (0.5)	81.4 (0.8)
	Change from baseline	-1.2 (0.6)	-1.0 (0.8)
	Placebo-corrected difference	-0.2 (0.8)	—
	95% CI	-1.9, 1.4	—
	P value	0.773	—

*Adjusted for baseline HbA1c, parameter measured, prior OADs, study and treatment.
^†Patient numbers varied for each parameter. For linagliptin, total cholesterol n = 351, LDL n = 349, HDL n = 348, triglycerides n = 349, SBP n = 359, DBP n = 359. For placebo, total cholesterol n = 140, LDL n = 139, HDL n = 140, triglycerides n = 139, SBP n = 144, DBP n = 144.
DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVOT, last value on treatment; SBP, systolic blood pressure.

ISSN: 1475-2840